Multi‐omic strategies applied to the study of pharmacoresistance in mesial temporal lobe epilepsy

Abstract

Abstract Mesial temporal lobe epilepsy (MTLE) is the most common type of focal epilepsy in adults, and hippocampal sclerosis (HS) is a frequent histopathological feature in patients with MTLE. Pharmacoresistance is present in at least one‐third of patients with MTLE with HS (MTLE+HS). Several hypotheses have been proposed to explain the mechanisms of pharmacoresistance in epilepsy, including the effect of genetic and molecular factors. In recent years, the increased knowledge generated by high‐throughput omic technologies has significantly improved the power of molecular genetic studies to discover new mechanisms leading to disease and response to treatment. In this review, we present and discuss the contribution of different omic modalities to understand the basic mechanisms determining pharmacoresistance in patients with MTLE+HS. We provide an overview and a critical discussion of the findings, limitations, new approaches, and future directions of these studies to improve the understanding of pharmacoresistance in MTLE+HS. However, it is important to point out that, as with other complex traits, pharmacoresistance to anti‐seizure medications is likely a multifactorial condition in which gene‐gene and gene‐environment interactions play an important role. Thus, studies using multidimensional approaches are more likely to unravel these intricate biological processes.

Keywords

• complex inheritance
• epigenomics
• metabolomics
• multifactorial inheritance
• pharmacogenomics
• proteomics